SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 224 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $400,233 | -9.6% | 14,517 | -1.4% | 0.00% | 0.0% |
| Q2 2023 | $442,633 | -18.0% | 14,725 | -1.2% | 0.00% | -25.0% |
| Q1 2023 | $539,826 | -2.2% | 14,900 | -3.7% | 0.00% | 0.0% |
| Q4 2022 | $551,992 | -17.2% | 15,475 | -21.5% | 0.00% | -33.3% |
| Q3 2022 | $667,000 | +17.0% | 19,710 | 0.0% | 0.01% | +20.0% |
| Q2 2022 | $570,000 | -10.5% | 19,710 | 0.0% | 0.01% | +25.0% |
| Q1 2022 | $637,000 | +6.5% | 19,710 | -4.0% | 0.00% | 0.0% |
| Q4 2021 | $598,000 | +28.3% | 20,525 | +17.3% | 0.00% | +33.3% |
| Q3 2021 | $466,000 | -19.5% | 17,495 | -7.0% | 0.00% | -25.0% |
| Q2 2021 | $579,000 | +17.2% | 18,815 | -0.3% | 0.00% | 0.0% |
| Q1 2021 | $494,000 | +47.0% | 18,875 | +41.3% | 0.00% | +33.3% |
| Q4 2020 | $336,000 | +19.1% | 13,355 | -1.3% | 0.00% | 0.0% |
| Q3 2020 | $282,000 | +25.3% | 13,535 | +42.6% | 0.00% | +50.0% |
| Q2 2020 | $225,000 | – | 9,490 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |